Clinical, radiological and serum amyloid P component scintigraphic features of β2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis

被引:23
作者
Tan, SY
Baillod, R
Brown, E
Farrington, K
Soper, C
Percy, M
Clutterbuck, E
Madhoo, S
Pepys, MB
Hawkins, PN
机构
[1] Hammersmith Hosp, Renal Unit, Med Immunol Unit, London, England
[2] Royal Free Hosp, London NW3 2QG, England
[3] Charing Cross Hosp, London, England
[4] Lister Hosp, Renal Unit, Stevenage, Herts, England
[5] St Helier Hosp, Renal Unit, Carshalton, Surrey, England
关键词
amyloid; beta(2)-microglobulin; peritoneal dialysis; serum amyloid P component; scintigraphy;
D O I
10.1093/ndt/14.6.1467
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. beta(2)-Microglobulin (beta 2M) amyloidosis occurs in patients with end-stage renal failure (ESRF) who undergo long-term continuous ambulatory peritoneal dialysis (CAPD), but its prevalence in patients treated exclusively by CAPD is unknown. In addition, its features may differ from those of haemodialysis-associated beta 2M amyloidosis because CAPD is more biocompatible. Methods. We performed serum amyloid P component (SAP) scintigraphy, a specific technique for imaging amyloid deposits, in 13 consecutive patients with ESRF who had been dialysed for >5 years, at least 80% of the time by CAPD. Clinical and radiological features of beta 2M amyloidosis were sought and compared with the results of SAP scintigraphy. Results. SAP scans showed articular amyloid deposits in seven patients, all of whom had evidence of carpal tunnel syndrome and four of whom had arthralgia characteristic of dialysis amyloidosis. Typical radiographic bone cysts were present in only one case who had been dialysed for >17 years. The remaining six patients had no clinical, radiological or scintigraphic evidence of beta 2M amyloidosis. Conclusions. The prevalence of beta 2M amyloidosis in this study was comparable with that in reported haemodialysis populations. Many of the amyloid deposits demonstrated by SAP scintigraphy were not associated with symptoms, but larger and longer term studies are required to determine whether CAPD favourably influences their clinical expression.
引用
收藏
页码:1467 / 1471
页数:5
相关论文
共 28 条
[1]   Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene [J].
Botto, M ;
Hawkins, PN ;
Bickerstaff, MCM ;
Herbert, J ;
Bygrave, AE ;
McBride, A ;
Hutchinson, WL ;
Tennent, GA ;
Walport, MJ ;
Pepys, MB .
NATURE MEDICINE, 1997, 3 (08) :855-859
[2]  
COLOMBI A, 1989, PERITON DIALYSIS INT, V9, P321
[3]   RHEUMATIC SYNDROMES AND BETA-2-MICROGLOBULIN AMYLOIDOSIS IN PATIENTS RECEIVING LONG-TERM PERITONEAL-DIALYSIS [J].
CORNELIS, F ;
BARDIN, T ;
FALLER, B ;
VERGER, C ;
ALLOUACHE, M ;
RAYMOND, P ;
ROTTEMBOURG, J ;
TOURLIERE, D ;
BENHAMOU, C ;
NOEL, LH ;
KUNTZ, D .
ARTHRITIS AND RHEUMATISM, 1989, 32 (06) :785-788
[4]   IMAGING OF DIALYSIS-RELATED AMYLOID (AB-AMYLOID) DEPOSITS WITH I-131 BETA-2-MICROGLOBULIN [J].
FLOEGE, J ;
BURCHERT, W ;
BRANDIS, A ;
GIELOW, P ;
NONNASTDANIEL, B ;
SPINDLER, E ;
HUNDESHAGEN, H ;
SHALDON, S ;
KOCH, KM .
KIDNEY INTERNATIONAL, 1990, 38 (06) :1169-1176
[5]   DIALYSIS - RELATED BETA-2 MICROGLOBULIN - AMYLOID ARTHROPATHY IMPROVEMENT OF CLINICAL SYMPTOMS AFTER A SWITCH OF DIALYSIS MEMBRANES [J].
HARDOUIN, P ;
FLIPO, RM ;
FOISSACGEGOUX, P ;
DUMONT, A ;
DUQUESNOY, B ;
DELCAMBRE, B .
CLINICAL RHEUMATOLOGY, 1988, 7 (01) :41-45
[6]   STUDIES WITH RADIOLABELED SERUM AMYLOID-P COMPONENT PROVIDE EVIDENCE FOR TURNOVER AND REGRESSION OF AMYLOID DEPOSITS IN-VIVO [J].
HAWKINS, PN .
CLINICAL SCIENCE, 1994, 87 (03) :289-295
[7]  
HAWKINS PN, 1988, LANCET, V1, P1413
[8]   METABOLIC STUDIES OF RADIOIODINATED SERUM AMYLOID-P COMPONENT IN NORMAL SUBJECTS AND PATIENTS WITH SYSTEMIC AMYLOIDOSIS [J].
HAWKINS, PN ;
WOOTTON, R ;
PEPYS, MB .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (06) :1862-1869
[9]   EVALUATION OF SYSTEMIC AMYLOIDOSIS BY SCINTIGRAPHY WITH I-123 LABELED SERUM AMYLOID-P COMPONENT [J].
HAWKINS, PN ;
LAVENDER, JP ;
PEPYS, MB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (08) :508-513
[10]  
HERMANN E, 1991, Z RHEUMATOL, V50, P160